Detalles de la búsqueda
1.
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.
J Antimicrob Chemother
; 77(9): 2506-2515, 2022 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35762503
2.
HIV-1-RNA and total HIV-1-DNA loads in the genital compartment in men receiving dolutegravir- versus darunavir-based combined ART (cART) regimens during primary HIV infection.
J Antimicrob Chemother
; 77(3): 735-739, 2022 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35195692
3.
The build-up of stock of stable integrated proviruses overtime explains the difficulty in reducing HIV-1 DNA levels when treatment is initiated at the chronic stage of the infection.
J Virus Erad
; 9(4): 100357, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38188640
4.
Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients.
AIDS
; 32(16): 2291-2299, 2018 10 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30096071
5.
Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.
AIDS Res Hum Retroviruses
; 23(9): 1105-13, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17919105
6.
A 5-year neutralizing immune response to yellow fever vaccine in HIV-infected and HIV-uninfected adults.
AIDS
; 36(2): 319-321, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34934023
7.
Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype.
PLoS One
; 12(5): e0177882, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28562615
8.
Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults.
AIDS
; 20(7): 1039-49, 2006 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-16603857
9.
Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals.
AIDS
; 20(3): 405-13, 2006 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-16439874
10.
Experience using MedDRA for global events coding in HIV clinical trials.
Contemp Clin Trials
; 27(1): 13-22, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16288902
11.
Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
AIDS
; 19(3): 279-86, 2005 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-15718838
12.
Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
J Clin Virol
; 33(2): 99-103, 2005 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15911424
13.
Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.
AIDS
; 16(18): 2447-54, 2002 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-12461419
14.
Final analysis of the Trilège induction-maintenance trial: results at 18 months.
AIDS
; 16(4): 561-8, 2002 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-11872999
15.
Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
Antivir Ther
; 8(1): 65-72, 2003 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-12713066
16.
Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
Antivir Ther
; 7(2): 113-21, 2002 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-12212923
17.
Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.
Vaccine
; 30(52): 7522-8, 2012 Dec 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-23103195
18.
Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial.
J Acquir Immune Defic Syndr
; 52(5): 531-7, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19855285
19.
A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients.
J Infect Dis
; 189(5): 862-70, 2004 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-14976604
20.
Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
Antimicrob Agents Chemother
; 46(6): 1906-13, 2002 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-12019107